Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 283

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 283
---
 on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than its current
expectations. Changing circumstances, some of which may be beyond the Company’s control, could result in less cash and cash equivalents
available to fund operations or cause the Company to consume capital significantly faster than currently anticipated, and the Company
may need to seek additional funds from additional sources sooner than planned.

37

Because
of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drug products,
the Company is unable to estimate the exact amount of its operating capital requirements. The Company’s future funding requirements
will depend on many factors, including, but not limited to those listed under “Factors Affecting Our Performance” above.

Identifying
potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process
that takes many years to complete, and the Company may never generate the necessary data or results required to obtain marketing approval
and achieve product sales. In addition, the Company’s product candidates, if approved, may not achieve commercial success. Commercial
revenues, if any, will be derived from sales of product candidates that the Company does not expect to be commercially available in the
near term, if at all. Accordingly, the Company will need to continue to rely on additional financing to achieve its business objectives.
Adequate additional financing may not be available to the Company on acceptable terms, or at all. To the extent that the Company raises
additional capital through the sale of equity or convertible debt securities, the terms of these equity securities or this debt may restrict
the Company’s ability to operate. Any future debt financing and equity financing, if available, may involve covenants limiting
and restricting the ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing
or other arrangements or declaring dividends. If the Company raises additional funds through collaborations, strategic alliances or marketing,
distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its technologies, future
revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to the Company. If the
Company is unable to raise capital when needed or on acceptable terms, the Company could be forced to delay, reduce or eliminate its
R&D programs or future commercialization efforts.

Cash
Flows

    For
    the Six Months Ended June 30,  

    2024